Structure of Capmatinib
CAS No.: 1029712-80-8
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
INCB28060 is a potent and selective c-MET kinase inhibitor. INCB28060 inhibits c-MET kinase activity with an average IC50 of 0.13 nM.
Synonyms: INCB28060; INC280; NVP-INC280
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1029712-80-8 |
Formula : | C23H17FN6O |
M.W : | 412.42 |
SMILES Code : | O=C(NC)C1=CC=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1F |
Synonyms : |
INCB28060; INC280; NVP-INC280
|
MDL No. : | MFCD18633285 |
InChI Key : | LIOLIMKSCNQPLV-UHFFFAOYSA-N |
Pubchem ID : | 25145656 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
WT and Tpl2−/−keratinocytes | 0.1 nM | 2 h | Capmatinib inhibited the HGF-stimulated p-MET and fully blocked the HGF-mediated increase in p-EGFR, restoring levels to baseline conditions. | PMC6328619 |
NF1-MET and NF1-P53 cells | 100 nM | 72 h | To evaluate the sensitivity of NF1-MET and NF1-P53 cells to Capmatinib, the results showed that NF1-P53 cells were resistant to Capmatinib and Trametinib as single agents and in combination therapy. | PMC11068581 |
PC3M cells | 10 nM | 24 h | To evaluate the effect of Capmatinib on the migration and invasion capacity of PC3M cells. Results showed that Capmatinib significantly reduced the migratory capacity of cells. | PMC11793009 |
PC3 cells | 10 nM | 24 h | To evaluate the effect of Capmatinib on the migration and invasion capacity of PC3 cells. Results showed that Capmatinib significantly reduced the migratory capacity of cells. | PMC11793009 |
EBC-1 | 1.5, 2.2, 2.4 μM | 2 months | To establish capmatinib-resistant NSCLC cell lines and evaluate their resistance mechanisms. Results showed that capmatinib-resistant NSCLC cells were dependent on alternative pathway activation. | PMC6639226 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
BALB/C nude mice | Orthotopic metastatic model | Oral | 10 mg/kg | Once daily for 8 weeks | To evaluate the inhibitory effect of Capmatinib combined with Defactinib on ETV1-induced HCC metastasis. | PMC9479266 |
Mice | Tpl2−/−mice | Dietary administration | 44 mg/kg | Continued for 52 weeks | Capmatinib treatment significantly reduced the overall tumor burden in Tpl2?/?mice and prevented all malignant conversion of benign papillomas to invasive SCC. | PMC6328619 |
Mice | MPNST xenograft model | Oral | 30 mg/kg | Twice daily for 15 days | To evaluate the impact of p53 loss on Capmatinib sensitivity, the results showed that Capmatinib significantly inhibited tumor growth in both NF1-MET and NF1-MET;sgP53 models, but only NF1-MET tumors regressed during treatment, while NF1-MET;sgP53 tumors remained stable, with a subset of tumors showing increased growth. | PMC11068581 |
Mice | NSG-hHGFki mice | Oral | 10 mg/kg | 5 days a week for 4 weeks | To evaluate the effect of Capmatinib on tumour growth in NSG-hHGFki mice. Results showed that Capmatinib significantly reduced the tumour volume induced by ETV1 and ERG overexpressing cells. | PMC11793009 |
Mice | Hepa1-6, HCA-1 and DEN HCC models | Oral | 10 mg/kg | Once daily for 5 days | The combination of Capmatinib with PD-1 blockade significantly enhanced antitumor efficacy in HCC models, particularly in the αPD-1 refractory DEN model, outperforming the type II inhibitor Cabozantinib. | PMC11529525 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03693339 | Cancer|Lung Cancer Metastatic|... More >>MET Gene Mutation Less << | PHASE2 | UNKNOWN | 2022-06-30 | Asan Medical Center, Seoul, 05... More >>505, Korea, Republic of Less << |
NCT05567055 | Non-small Cell Lung Cancer | PHASE2 | WITHDRAWN | 2025-09-28 | - |
NCT02019693 | Kidney Cancer | PHASE2 | COMPLETED | 2021-12-17 | National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less << |
NCT02414139 | Carcinoma, Non-Small-Cell Lung | PHASE2 | COMPLETED | 2023-05-16 | Pacific Shores Medical Group S... More >>C, Long Beach, California, 90813, United States|University Of California Los Angeles Dept of Onc, Los Angeles, California, 90095, United States|University of California Irvine Medical Center Chao Family Chao Family Comp Cancer Center, Orange, California, 92868, United States|H Lee Moffitt Cancer Center and Research Institute ., Tampa, Florida, 33612, United States|University of Iowa Hospitals and Clinics SC-3, Iowa City, Iowa, 52242, United States|Massachusetts General Hospital MGH Cancer Center, Boston, Massachusetts, 02114, United States|VA Ann Arbor Health System VA Ann Arbor Health System, Ann Arbor, Michigan, 48105, United States|Mayo Clinic Rochester ., Rochester, Minnesota, 55905, United States|Oregon Health and Science University SC, Portland, Oregon, 97239, United States|Lehigh Valley Health Network SC, Allentown, Pennsylvania, 18103, United States|Andrew and Patel Associates, Camp Hill, Pennsylvania, 17011, United States|Mays Cancer Ctr Uthsa Mdacc SC-5, San Antonio, Texas, 78229, United States|University of Utah / Huntsman Cancer Institute Oncology, Salt Lake City, Utah, 84103, United States|Novartis Investigative Site, Caba, Buenos Aires, C1426ANZ, Argentina|Novartis Investigative Site, Buenos Aires, Caba, C1431FWO, Argentina|Novartis Investigative Site, La Rioja, 5300, Argentina|Novartis Investigative Site, Wien, 1210, Austria|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, 13915, France|Novartis Investigative Site, Dijon, Cote D Or, 21034, France|Novartis Investigative Site, Clermont-Ferrand, 63011, France|Novartis Investigative Site, La Tronche, 38700, France|Novartis Investigative Site, Lille, 59000, France|Novartis Investigative Site, Marseille, 13273, France|Novartis Investigative Site, Paris, 75970, France|Novartis Investigative Site, Pierre Benite, 69495, France|Novartis Investigative Site, Rennes, 35043, France|Novartis Investigative Site, Strasbourg Cedex, 67091, France|Novartis Investigative Site, Heidelberg, Baden-Württemberg, 69126, Germany|Novartis Investigative Site, Berlin, 13125, Germany|Novartis Investigative Site, Frankfurt, 60590, Germany|Novartis Investigative Site, Gottingen, 37075, Germany|Novartis Investigative Site, Halle (Saale), 06120, Germany|Novartis Investigative Site, Hamburg, 20251, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Homburg, 66421, Germany|Novartis Investigative Site, Koeln, 50937, Germany|Novartis Investigative Site, Muenchen, 81925, Germany|Novartis Investigative Site, Nuernberg, 90419, Germany|Novartis Investigative Site, Ravensburg, 88214, Germany|Novartis Investigative Site, Tuebingen, 72076, Germany|Novartis Investigative Site, Ulm, 89081, Germany|Novartis Investigative Site, Ramat Gan, 52621, Israel|Novartis Investigative Site, Tel Aviv, 6423906, Israel|Novartis Investigative Site, Bologna, BO, 40138, Italy|Novartis Investigative Site, Brescia, BS, 25123, Italy|Novartis Investigative Site, Catania, CT, 95124, Italy|Novartis Investigative Site, Catanzaro, CZ, 88100, Italy|Novartis Investigative Site, Meldola, FC, 47014, Italy|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Monza, MB, 20900, Italy|Novartis Investigative Site, Milano, MI, 20141, Italy|Novartis Investigative Site, Milano, MI, 20162, Italy|Novartis Investigative Site, Modena, MO, 41124, Italy|Novartis Investigative Site, Roma, RM, 00155, Italy|Novartis Investigative Site, Verona, VR, 37126, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Nagoya, Aichi, 464 8681, Japan|Novartis Investigative Site, Nagoya, Aichi, 466 8560, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, 811-1395, Japan|Novartis Investigative Site, Akashi, Hyogo, 673-8558, Japan|Novartis Investigative Site, Sendai city, Miyagi, 980 0873, Japan|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan|Novartis Investigative Site, Osaka Sayama, Osaka, 589 8511, Japan|Novartis Investigative Site, Chuo ku, Tokyo, 104 0045, Japan|Novartis Investigative Site, Koto ku, Tokyo, 135 8550, Japan|Novartis Investigative Site, Ube-city, Yamaguchi, 755-0241, Japan|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, 13620, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, 10408, Korea, Republic of|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Ashrafieh, 166830, Lebanon|Novartis Investigative Site, Mexico, Distrito Federal, 14080, Mexico|Novartis Investigative Site, Amsterdam, 1066 CX, Netherlands|Novartis Investigative Site, Groningen, 9713 GZ, Netherlands|Novartis Investigative Site, Maastricht, 6229 HX, Netherlands|Novartis Investigative Site, Rotterdam, 3015 GD, Netherlands|Novartis Investigative Site, Oslo, NO 0424, Norway|Novartis Investigative Site, Moscow, 109028, Russian Federation|Novartis Investigative Site, Saint Petersburg, 192148, Russian Federation|Novartis Investigative Site, Tambov, 392000, Russian Federation|Novartis Investigative Site, Singapore, 119228, Singapore|Novartis Investigative Site, Singapore, 168583, Singapore|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain|Novartis Investigative Site, Oviedo, Asturias, 33011, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain|Novartis Investigative Site, La Coruna, Galicia, 15006, Spain|Novartis Investigative Site, Madrid, 28034, Spain|Novartis Investigative Site, Madrid, 28041, Spain|Novartis Investigative Site, Stockholm, SE-171 76, Sweden|Novartis Investigative Site, Kaohsiung, 82445, Taiwan|Novartis Investigative Site, Taipei, 10002, Taiwan|Novartis Investigative Site, Taoyuan, 33305, Taiwan|Novartis Investigative Site, Birmingham, B9 5SS, United Kingdom|Novartis Investigative Site, London, W6 8RF, United Kingdom Less << |
NCT02474537 | Hepatic Impairment | PHASE1 | COMPLETED | 2017-09-12 | University of Miami Miller Sch... More >>ool of Medicine Clinical Resea Oncology, Miami, Florida, 33136, United States|Clinical Pharmacology of Miami, LLC., Miami, Florida, 33142, United States|Orlando Clinical Research Center, Orlando, Florida, 32086, United States|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States|Duke University Medical Center Oncology, Durham, North Carolina, 27710, United States Less << |
NCT01546428 | Advanced Solid Tumor | PHASE1 | COMPLETED | 2025-01-16 | Novartis Investigative Site, K... More >>ashiwa, Chiba, 277-8577, Japan|Novartis Investigative Site, Fukuoka, 811-1395, Japan Less << |
NCT05154344 | MET Alterations|Non Small Cell... More >> Lung Cancer|METex14 Mutations Less << | COMPLETED | 2022-02-01 | CHU, Lille, France|CHU, Tours,... More >> France Less << | |
NCT01737827 | Advanced Hepatocellular Carcin... More >>oma With c-MET Dysregulation Less << | PHASE2 | TERMINATED | 2023-05-24 | Novartis Investigative Site, N... More >>anjing, Jiangsu, 210002, China|Novartis Investigative Site, Xi'an, Shanxi, 710032, China|Novartis Investigative Site, Hangzhou, Zhejiang, 310016, China|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Singapore, 168583, Singapore|Novartis Investigative Site, Khon Kaen, THA, 40002, Thailand|Novartis Investigative Site, Bangkok, 10330, Thailand|Novartis Investigative Site, Bangkok, 10700, Thailand Less << |
NCT05675683 | Metastatic Non-Small Cell Lung... More >> Cancer Less << | COMPLETED | 2021-12-31 | 18 Novartis Investigative Site... More >>s in the US, East Hanover, New Jersey, 07936-1080, United States Less << | |
NCT03240393 | Carcinoma|Non-Small-Cell Lung ... More >>Cancer Less << | PHASE2 | WITHDRAWN | 2021-10-26 | - |
NCT02925104 | cMET Dysegulation Advanced Sol... More >>id Tumors Less << | PHASE1 | COMPLETED | 2018-05-16 | Indiana University Simon Cance... More >>r Center SC, Indianapolis, Indiana, 46202, United States|Novartis Investigative Site, Salzburg, 5020, Austria|Novartis Investigative Site, Herlev, 2730, Denmark|Novartis Investigative Site, Dresden, 01307, Germany|Novartis Investigative Site, Mainz, 55131, Germany|Novartis Investigative Site, Nijmegen, 6500 HB, Netherlands|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, 15706, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Madrid, 28040, Spain|Novartis Investigative Site, Zaragoza, 50009, Spain|Novartis Investigative Site, Goteborg, 413 45, Sweden|Novartis Investigative Site, Lund, SE-221 85, Sweden|Novartis Investigative Site, Stockholm, 171 76, Sweden|Novartis Investigative Site, Uppsala, SE-751 85, Sweden|Novartis Investigative Site, London, W1G 6AD, United Kingdom|Novartis Investigative Site, Manchester, M20 4BX, United Kingdom Less << |
NCT04741789 | Carcinoma, Non-Small Cell Lung... More >>|Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer Less << | AVAILABLE | - | - | |
NCT01324479 | Solid Tumors | PHASE1 | COMPLETED | 2017-07-04 | Highlands Oncology Group, Faye... More >>tteville, Arkansas, 72703, United States|University of Chicago SC, Chicago, Illinois, 60637, United States|Karmanos Cancer Institute Wayne St Karmanos, Detroit, Michigan, 48201, United States|Sarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, 37203, United States|University of Texas/MD Anderson Cancer Center Dept of Onc, Houston, Texas, 77030-4009, United States|Novartis Investigative Site, Westmead, New South Wales, 2145, Australia|Novartis Investigative Site, Woolloongabba, Queensland, 4102, Australia|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada|Novartis Investigative Site, La Tronche, 38700, France|Novartis Investigative Site, LILLE Cédex, 59037, France|Novartis Investigative Site, Strasbourg Cedex, 67091, France|Novartis Investigative Site, Essen, 45147, Germany|Novartis Investigative Site, Frankfurt, 60590, Germany|Novartis Investigative Site, Freiburg, 79106, Germany|Novartis Investigative Site, Gottingen, 37075, Germany|Novartis Investigative Site, Hannover, 30625, Germany|Novartis Investigative Site, Oldenburg, 26121, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Haifa, 3525408, Israel|Novartis Investigative Site, Kfar Saba, 4428164, Israel|Novartis Investigative Site, Ramat Gan, 5265601, Israel|Novartis Investigative Site, Tel Aviv, 6423906, Israel|Novartis Investigative Site, Ancona, AN, 60126, Italy|Novartis Investigative Site, Meldola, FC, 47014, Italy|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Milano, MI, 20162, Italy|Novartis Investigative Site, Reggio Emilia, RE, 42123, Italy|Novartis Investigative Site, Seoul, Gyeonggi Do, 03080, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, 10408, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, 05505, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, 06351, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, 06591, Korea, Republic of|Novartis Investigative Site, Utrecht, The Netherlands, 3508 GA, Netherlands|Novartis Investigative Site, Amsterdam, 1066 CX, Netherlands|Novartis Investigative Site, Rotterdam, 3075 EA, Netherlands|Novartis Investigative Site, Oslo, NO-0424, Norway|Novartis Investigative Site, Singapore, 169610, Singapore|Novartis Investigative Site, Granada, Andalucia, 18014, Spain|Novartis Investigative Site, Oviedo, Asturias, 33006, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Madrid, 28046, Spain|Novartis Investigative Site, Zaragoza, 50009, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, 70403, Taiwan|Novartis Investigative Site, Taipei, Taiwan ROC, 10041, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, 90110, Thailand Less << |
NCT04460729 | Non-small Cell Lung Carcinoma ... More >>(NSCLC) Less << | PHASE2 | WITHDRAWN | 2023-11-17 | - |
NCT04677595 | Non-Small Cell Lung Cancer (NS... More >>CLC) Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-12-31 | Novartis Investigative Site, X... More >>iamen, Fujian, 361001, China|Novartis Investigative Site, Foshan, Guangdong, 528000, China|Novartis Investigative Site, Guang Zhou, Guangdong, 510120, China|Novartis Investigative Site, Guangzhou, Guangdong, 510080, China|Novartis Investigative Site, Guangzhou, Guangdong, 510515, China|Novartis Investigative Site, Harbin, Heilongjiang, 150081, China|Novartis Investigative Site, Zhengzhou, Henan, 450003, China|Novartis Investigative Site, Wuhan, Hubei, 430022, China|Novartis Investigative Site, Shenyang, Liaoning, 110011, China|Novartis Investigative Site, Jinan, Shandong, 250117, China|Novartis Investigative Site, Shanghai, Shanghai, 200032, China|Novartis Investigative Site, Shanghai, Shanghai, 200433, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Kunming, Yunnan, 650106, China|Novartis Investigative Site, Hangzhou, Zhejiang, 310022, China|Novartis Investigative Site, Beijing, 100036, China|Novartis Investigative Site, Tianjin, 300052, China Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.42mL 0.48mL 0.24mL |
12.12mL 2.42mL 1.21mL |
24.25mL 4.85mL 2.42mL |
|
Dissolving Methods |
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|
Tags: Capmatinib | INC280 | INCB28060 | INC 280 | INC-280 | INCB28060 | INCB 28060 | INCB-28060 | c-Met/HGFR | Apoptosis | orally active | ATP competitive | SNU-5 | S114 | H441 | U-87MG | Balb/c nu/nu mice | 1029712-80-8
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL